The ICBs show promising efficacy in NSCLC patients with significant clinical benefits and durable responses, but the overall response rate to anti PD-1/PD-L1 therapy is only 20–30% [4,5]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.